Stock listing
Eloxx Pharmaceuticals, Inc.
Selected listing: ELOX · NASDAQ · USD · US
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), Health Technology. Latest release Sep 11, 2026: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b…
- Ticker
- NASDAQ:ELOX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Eloxx Pharmaceuticals, Inc.
The company focuses on developing innovative therapies for genetic diseases caused by nonsense mutations. Eloxx aims to address significant unmet medical needs through its research and development efforts.
Latest news from Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 11, 2026
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity
May 5, 2026
ELOX: Sixth Amendment adds bridge and Tranche 2 loans, PIK interest, and new agent SD MF 4 LLC
March 17, 2026
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
Research Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. company profile
View the public company page for Eloxx Pharmaceuticals, Inc. on 6ix.
Eloxx Pharmaceuticals, Inc. news
Read company news and market updates connected to Eloxx Pharmaceuticals, Inc..
Eloxx Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Eloxx Pharmaceuticals, Inc..